Assessment of therapy response in lung cancer with18F-α- methyl tyrosine PET

American Journal of Roentgenology

Volumn 195, Issue 5, 2010, Pages 1204-1211

  Kaira, Kyoichi ^a   Oriuchi, Noboru ^a   Yanagitani, Noriko ^a   Sunaga, Noriaki ^a   Ishizuka, Tamotsu ^a   Mori, Masatomo ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18f methyl tyrosine; FDG; FMT; Lung cancer; PET; Therapy response

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA METHYL TRYOSINE F 18; AMRUBICIN; CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MALE; MEDIASTINUM LYMPH NODE; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALPHA-METHYLTYROSINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78649694774     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.09.4167     Document Type: Article

References (33)

1. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261
2. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron- emission tomography and computed tomography. N Engl J Med 2003; 348:2500-2507 (Pubitemid 36706537)
3. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16:2142-2149
4. Weber W, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006; 33[suppl 1]:S27-S37
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
6. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small- cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106
7. Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 2008; 59:203-210
8. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007; 110:1654-1664
9. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131:1019-1027
10. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002; 61:729-737
11. Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18- alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13:6369-6378
12. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 2005; 15:254-266
13. Kaira K, Oriuchi N, Imai H, et al. L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci 2008; 99:2380-2386
14. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 2008; 98:742-748
15. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 2009; 100:249-254
16. Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg 2007; 83:1826-1830
17. Kaira K, Sunaga N, Yanagitani N, et al. A phase I dose escalation study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Anticancer Drugs 2007; 18:471-476 (Pubitemid 46712411)
18. Kaira K, Sunaga N, Yanagiani N, et al. Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anticancer Drugs 2008; 19:289-294
19. Kaira K, Sunaga N, Yanagitani N, et al. Phase I study of oral S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 75:109-114
20. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun 1997; 18:169-175
21. Oriuchi N, Tomiyoshi K, Inoue T, et al. Independent thallium-201 accumulation and fluorine-18- fluorodeoxyglucose metabolism in glioma. J Nucl Med 1996; 37:457-462
22. 18F]-α-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39:663-667
23. Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value (SUV) measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999; 20: 849-857
24. 18F] fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. J Clin Oncol 2007; 25:3116-3123
25. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782
26. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERSIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50[suppl]:122S-147S
27. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004; 78:1903-1909
28. Mac Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49: 95-108
29. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273:23,629-23,632
30. 18F-fluoroethyl)-L-tyrosine in peripheral tumors: first clinical results. J Nucl Med 2005; 46: 411-416
31. 18F] fluoromethyl-L-tyrosine is a potential tracer for monitoring tumor response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine. Eur J Nucl Med Mol Imaging 2006; 33:1134-1139
32. Kubota K, Matsuzawa T, Takahashi T, et al. Rapid and sensitive response of carbon-11-L-methionine tumor uptake to irradiation. J Nucl Med 1989; 30: 2012-2016
33. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11] tyrosine and L- [methyl-carbon-11] methionine to assess liver protein synthesis by PET. J Nucl Med 1996; 37:279-285